Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
TORONTO, Oct.
15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S.
Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States.
Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter.
Edesa anticipates that topline data will be available fourth quarter 2027.
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
